Literature DB >> 17298847

Characterization of immune complexes of idiotypic catalytic and anti-idiotypic inhibitory antibodies in plasma of type 1 diabetic subjects.

Andrea Pagetta1, Elisa Tramentozzi, Lorisa Corbetti, Martina Frasson, Anna M Brunati, Paola Finotti.   

Abstract

An increase in proteolytic activity is an early common feature of diabetes, and is associated with the development of vascular complications. We performed an extensive proteomic investigation on plasma of type 1 diabetic subjects to discover why some of them apparently lacked any measurable proteolytic activity. Activity was found enclosed in immune complexes in which Fab/(Fab)(2) displayed a serine-like catalytic activity. Disaggregation of complexes by means of Protein G affinity chromatography led to the separation of free subunits of Fab, showing a specific amidolytic activity, from Fab that displayed activity on casein and remained closely complexed with whole IgG. On both types of Fab the serine catalytic site appeared to be the same, being located in close vicinity to the antigen-binding site. The distinct substrate specificity was due to the different conformation adopted by the catalytic site depending on the structure of Fab/(Fab)(2), whether in complexes or as free subunits. Catalytic Fab/(Fab)(2) originated from idiotypic antibodies developed against Grp94, identified as the primary antigen covalently complexed with Fab. Whole IgG present in immune complexes were instead mostly formed with anti-idiotypic antibodies developed against the adduct of Fab/(Fab)(2) with Grp94, and were responsible for blocking any catalytic activity. In dot-blot experiments with native Grp94, we confirmed that in any diabetic plasma circulated anti-Grp94, idiotypic, and anti-idiotypic antibodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17298847     DOI: 10.1016/j.molimm.2007.01.012

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  Defective Proinsulin Handling Modulates the MHC I Bound Peptidome and Activates the Inflammasome in β-Cells.

Authors:  Muhammad Saad Khilji; Pouya Faridi; Erika Pinheiro-Machado; Carolin Hoefner; Tina Dahlby; Ritchlynn Aranha; Søren Buus; Morten Nielsen; Justyna Klusek; Thomas Mandrup-Poulsen; Kirti Pandey; Anthony W Purcell; Michal T Marzec
Journal:  Biomedicines       Date:  2022-03-30

2.  Proteomic Investigation on Grp94-IgG Complexes Circulating in Plasma of Type 1 Diabetic Subjects.

Authors:  Antonella Roveri; Mattia Zaccarin; Andrea Pagetta; Elisa Tramentozzi; Paola Finotti
Journal:  J Diabetes Res       Date:  2015-06-08       Impact factor: 4.011

3.  Structural insights into complexes of glucose-regulated Protein94 (Grp94) with human immunoglobulin G. relevance for Grp94-IgG complexes that form in vivo in pathological conditions.

Authors:  Andrea Pagetta; Elisa Tramentozzi; Elena Tibaldi; Laura Cendron; Giuseppe Zanotti; Anna Maria Brunati; Maurizio Vitadello; Luisa Gorza; Paola Finotti
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

4.  A mutant α1antitrypsin in complex with heat shock proteins as the primary antigen in type 1 diabetes in silico investigation.

Authors:  Paola Finotti; Andrea Pagetta
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

5.  Angiogenic transforming capacity of IgG purified from plasma of type 1 diabetic patients.

Authors:  Elisa Tramentozzi; Andrea Pagetta; Martina Frasson; Anna Maria Brunati; Monica Montopoli; Paola Finotti
Journal:  J Cell Mol Med       Date:  2008-04-18       Impact factor: 5.310

6.  Grp94 in complexes with IgG is a soluble diagnostic marker of gastrointestinal tumors and displays immune-stimulating activity on peripheral blood immune cells.

Authors:  Elisa Tramentozzi; Erlis Ruli; Imerio Angriman; Romeo Bardini; Michela Campora; Vincenza Guzzardo; Rita Zamarchi; Elisabetta Rossi; Massimo Rugge; Paola Finotti
Journal:  Oncotarget       Date:  2016-11-08

7.  Immunoglobulins with Non-Canonical Functions in Inflammatory and Autoimmune Disease States.

Authors:  Evgeny A Ermakov; Georgy A Nevinsky; Valentina N Buneva
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.